Arrowhead’s plozasiran clears CHMP: what a positive opinion for FCS means for siRNA’s regulatory arc in Europe
Plozasiran clears CHMP but the real test is reimbursement. Europe's HTA bodies will now decide whether clinical FCS diagnosis is enough.
Pharma & Biotech
Pharma & Biotech
Merck’s Terns deal clears antitrust hurdle as TERN-701 becomes bigger oncology test
Merck cleared one deal hurdle. TERN-701 still has to prove whether chronic myeloid leukemia can justify a $6.7 billion bet.
Pharma & Biotech
Can Bristol Myers Squibb and Pfizer protect Eliquis growth as drug pricing pressure rises?
Eliquis faces pricing pressure, but Bristol Myers Squibb and Pfizer are moving first. Direct access may become pharma’s new defence.
Medical Devices & Diagnostics
Can BrioHealth’s Brio4Kids trial close the pediatric LVAD gap in advanced heart failure?
Pediatric heart failure lacks durable LVAD choices. BrioHealth’s Brio4Kids trial now tests whether BrioVAD can narrow that gap.
Medical Devices & Diagnostics
Is EASYMADE TI the breakthrough CGBIO needs in patient-specific craniofacial reconstruction?
Customized implants are moving from niche to surgical workflow. CGBIO’s U.S. clearance tests whether speed can become a medtech edge.
Medical Devices & Diagnostics
Vapotherm FDA clearance expands HVT 2.0 use from neonatal to adult respiratory care
Find out how Vapotherm’s FDA-cleared All Patient Circuit could simplify high velocity therapy from neonatal to adult care.
Medical Devices & Diagnostics
Why Sonorous Neurovascular’s BosCATH FDA clearance could matter more than it first appears
Find out how Sonorous Neurovascular’s BosCATH FDA clearance strengthens its neurovascular access strategy today!
Pharma & Biotech
What LEVI-04 data suggest about the future of disease-modifying osteoarthritis therapies
LEVI-04 Phase II data from Levicept Ltd. signal a shift in osteoarthritis treatment. Discover what this means for disease-modifying therapies.
Pharma & Biotech
How Novartis Pharma AG is targeting the last untreated segment in malaria care
Discover how Novartis Pharma AG is targeting neonatal malaria with Coartem Baby and what WHO prequalification means for global access.
Pharma & Biotech
Why Novartis Pharma AG’s Itvisma could redefine treatment pathways for older SMA patients
Novartis Pharma AG’s Itvisma gains CHMP support in SMA. Find out how gene therapy could reshape treatment for older patients in Europe.